565 related articles for article (PubMed ID: 23236167)
1. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
[TBL] [Abstract][Full Text] [Related]
4. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
6. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
9. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
[TBL] [Abstract][Full Text] [Related]
10. The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.
Turgeon N; Blais M; Delabre JF; Asselin C
J Cell Biochem; 2013 May; 114(5):1203-15. PubMed ID: 23192652
[TBL] [Abstract][Full Text] [Related]
11. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
12. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.
Wilson BG; Wang X; Shen X; McKenna ES; Lemieux ME; Cho YJ; Koellhoffer EC; Pomeroy SL; Orkin SH; Roberts CW
Cancer Cell; 2010 Oct; 18(4):316-28. PubMed ID: 20951942
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
15. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Zhang Q; Padi SK; Tindall DJ; Guo B
Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
[TBL] [Abstract][Full Text] [Related]
16. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
17. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
18. Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence.
Agherbi H; Gaussmann-Wenger A; Verthuy C; Chasson L; Serrano M; Djabali M
PLoS One; 2009 May; 4(5):e5622. PubMed ID: 19462008
[TBL] [Abstract][Full Text] [Related]
19. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
